Related Experiment Videos
Recent advances in salmonellosis treatment based on in vitro susceptibilities
A G Paradelis1, T Edipides, W Zurukzoglou
1Department of Experimental Pharmacology, Medical Faculty, Aristotelian University of Thessaloniki, Greece.
Abstract:
Chloramphenicol-resistant strains of Salmonella typhi (MIC 60 micrograms/ml), chloramphenicol and ampicillin-resistant strains of Salmonella typhimurium as well as multiresistant strains of various salmonella serotypes were found to be very sensitive to cephradine (MIC 0.078-0.625 micrograms/ml). Ten patients with Salmonella typhi bacteremia were successfully treated with cephradine; all the patients' strains were chloramphenicol-resistant. Cephradine appears to warrant further clinical trial for the treatment of salmonellosis.
Insights
Cephradine shows high efficacy against multidrug-resistant Salmonella strains, including Salmonella typhi. Clinical trials demonstrated successful treatment of Salmonella typhi bacteremia with cephradine, suggesting its potential for salmonellosis therapy.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Antimicrobial resistance in Salmonella serotypes poses a significant public health challenge.
- Multidrug-resistant Salmonella strains, particularly Salmonella typhi, necessitate alternative treatment options.
- Chloramphenicol resistance is a growing concern in the management of typhoid fever.
Purpose of the Study:
- To evaluate the in vitro susceptibility of various Salmonella serotypes to cephradine.
- To assess the clinical efficacy of cephradine in treating patients with Salmonella typhi bacteremia.
- To determine the potential of cephradine as a therapeutic agent for salmonellosis.
Main Methods:
- In vitro antimicrobial susceptibility testing (MIC determination) of Salmonella isolates against cephradine.
- Clinical case series of patients diagnosed with Salmonella typhi bacteremia.
- Treatment monitoring and patient outcome assessment for those receiving cephradine.
Main Results:
- Salmonella strains, including chloramphenicol-resistant Salmonella typhi and multidrug-resistant Salmonella typhimurium, exhibited high sensitivity to cephradine (MIC 0.078-0.625 µg/ml).
- Ten patients with chloramphenicol-resistant Salmonella typhi bacteremia achieved successful clinical outcomes with cephradine treatment.
- Cephradine demonstrated potent activity against resistant Salmonella isolates in vitro and in vivo.
Conclusions:
- Cephradine is a promising antibiotic for treating infections caused by multidrug-resistant Salmonella.
- Successful clinical treatment of Salmonella typhi bacteremia with cephradine supports its further investigation.
- Cephradine warrants expanded clinical trials for the effective management of salmonellosis.